Exelixis (NASDAQ:EXEL) had a great day in the market today, up 23% on the news that its drug cobimetinib in combination with Roche's (NASDAQOTH:RHHBY) drug Zelboraf succeeded in a phase 3 trial's primary endpoint of extending progression-free survival.

Of course, cobimetinib isn't all investors should think about regarding Exelixis: Cometriq will also be important. In the video below, health care analysts Michael Douglass and David Williamson give their take on Exelixis.